Innoviva

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Innoviva and other ETFs, options, and stocks.

About INVA

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. 

CEO
Pavel Raifeld
CEOPavel Raifeld
Employees
159
Employees159
Headquarters
Burlingame, California
HeadquartersBurlingame, California
Founded
1996
Founded1996
Employees
159
Employees159

INVA Key Statistics

Market cap
1.64B
Market cap1.64B
Price-Earnings ratio
6.88
Price-Earnings ratio6.88
Dividend yield
Dividend yield
Average volume
829.10K
Average volume829.10K
High today
$22.51
High today$22.51
Low today
$21.97
Low today$21.97
Open price
$22.33
Open price$22.33
Volume
640.88K
Volume640.88K
52 Week high
$25.15
52 Week high$25.15
52 Week low
$16.52
52 Week low$16.52

Stock Snapshot

Innoviva(INVA) stock is priced at $22.18, giving the company a market capitalization of 1.64B. It carries a P/E multiple of 6.88.

On 2026-03-05, Innoviva(INVA) stock moved within a range of $21.97 to $22.51. With shares now at $22.18, the stock is trading +1.0% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 640.88K, compared to an average daily volume of 829.1K.

Over the past 52 weeks, Innoviva(INVA) stock has traded between a high of $25.15 and a low of $16.52.

Over the past 52 weeks, Innoviva(INVA) stock has traded between a high of $25.15 and a low of $16.52.

INVA News

Simply Wall St 22h
Assessing Innoviva Valuation After Strong Earnings Growth And Portfolio Expansion

Advertisement Why Innoviva’s latest earnings matter for shareholders Innoviva (INVA) just posted fourth quarter and full year 2025 results, highlighted by hig...

Assessing Innoviva Valuation After Strong Earnings Growth And Portfolio Expansion
Simply Wall St 4d
Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva

Innoviva, Inc. recently reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, capping a full year in which revenue reac...

Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva

People also own

Based on the portfolios of people who own INVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.